NEW ZEALAND DATA SHEET

1. PRODUCT NAME

TEGRETOL® 200 mg Tablets
TEGRETOL® 400 mg Tablets
TEGRETOL® 200 mg CR Tablets
TEGRETOL® 400 mg CR Tablets
TEGRETOL® 100 mg / 5 mL Syrup

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substance

Tablets
- 200 mg: Each tablet contains 200 mg carbamazepine
- 400 mg: Each tablet contains 400 mg carbamazepine

CR tablets
- 200 mg: Each modified-release film-coated, divisible tablet contains 200 mg carbamazepine
- 400 mg: Each modified-release film-coated, divisible tablet contains 400 mg carbamazepine

Syrup
- 5 mL: Each 5 mL of syrup contains 100 mg carbamazepine

For a full list of excipients, see section 6.1. The syrup contains propylene glycol (refer to section 4.4, subsection Excipients of known effect).

3. PHARMACEUTICAL FORM

- Tablet containing 200 mg carbamazepine. Round, white, flat tablet, 9mm in diameter, with bevelled edges. Imprinted CG on one side, and G/K on the scored side. The tablet can be divided into equal doses.
- Tablet containing 400 mg carbamazepine. White, flat, rod-shaped tablet with bevelled edges. 17mm in length and 5.5mm in width. Imprinted CG/CG on one side and LR/LR on the second side; both sides of the tablet are scored. The tablet can be divided into equal doses.
- Controlled Release Tablet containing 200 mg carbamazepine. Beige-orange, ovaloid-shaped, film-coated divisible tablet with slightly convex faces. Approximate length is 12.2 mm, and approximate width is 5.6 mm. Both sides are scored; one side is imprinted C/G, and the other side H/C.
- Controlled Release Tablet containing 400 mg carbamazepine. Brown-orange, ovaloid-shaped, film-coated divisible tablet, with slightly convex faces. Approximately 16.7 mm in length, and approximately 6.6 mm in width. Imprinted CG/CG on one side, and ENE/ENE on the other side; both sides are scored.
- Syrup containing 100 mg/5mL carbamazepine. A viscous white suspension with a caramel odour and taste. It contains sorbitol (875 mg/5 mL), which is converted slowly into glucose, making the syrup suitable for diabetics.
4. CLINICAL PARTICULARS

4.1 Therapeutic indications

- Epilepsy
  - Complex or simple partial seizures (with or without loss of consciousness) with or without secondary generalization.

  Tegretol® is suitable for both monotherapy and combination therapy.

  Tegretol is usually not effective in absences (petit mal) and myoclonic seizures (see Warnings and precautions). Tegretol should not be used for status epilepticus.

- Acute mania and maintenance treatment of bipolar affective disorders to prevent or attenuate recurrence.

- Alcohol-withdrawal syndrome.

- Idiopathic trigeminal neuralgia and trigeminal neuralgia due to multiple sclerosis (either typical or atypical). Idiopathic glossopharyngeal neuralgia.

- Painful diabetic neuropathy.

- Diabetes insipidus centralis. Polyuria and polydipsia of neurohormonal origin.

4.2 Posology and method of administration

**Dosage**

**Epilepsy**
When possible, Tegretol should be prescribed as monotherapy.

Treatment should be initiated with a low daily dosage, to be slowly increased until an optimal effect is obtained.

The dose of carbamazepine should be adjusted to the needs of the individual patient to achieve adequate control of seizures. Determination of plasma levels may help in establishing the optimum dosage. In the treatment of epilepsy, the dose of carbamazepine usually requires total plasma-carbamazepine concentrations of about 4 to 12 micrograms/mL (17 to 50 micromoles/litre) (see Warnings and precautions, & Pharmacokinetics: absorption).

When Tegretol is added to existing antiepileptic therapy, this should be done gradually while maintaining or, if necessary, adapting the dosage of the other antiepileptic(s) (see Interactions).

**Adult dosage**

**Epilepsy**
Initially, 100 to 200 mg once or twice daily; the dosage should be slowly raised until – generally at 400 mg 2 to 3 times daily – an optimum response is obtained. In some patients 1600 mg or even 2000 mg daily may be appropriate.

**Acute mania and maintenance treatment of bipolar affective disorders**
Dosage range: about 400 to 1600 mg daily, the usual dosage being 400 to 600 mg daily given in 2 to 3 divided doses. In acute mania, the dosage should be increased rather quickly, whereas
small dosage increments are recommended for maintenance therapy of bipolar disorders in order to ensure optimal tolerability.

**Alcohol-withdrawal syndrome**
Average dosage: 200 mg 3 times daily. In severe cases, it can be raised during the first few days (e.g. to 400 mg 3 times daily). At the start of treatment for severe withdrawal manifestations, Tegretol should be given in combination with sedative-hypnotic drugs (e.g. clomethiazole, chlordiazepoxide). After the acute stage has abated, Tegretol can be continued as monotherapy.

**Trigeminal neuralgia**
The initial dosage of 200 to 400 mg should be slowly raised daily until freedom from pain is achieved (normally at 200 mg 3 to 4 times daily). The dosage should then be gradually reduced to the lowest possible maintenance level. Maximum recommended dose is 1200 mg/day. When pain relief has been obtained, attempts should be made to gradually discontinue therapy, until another attack occurs.

**Painful diabetic neuropathy**
Average dosage: 200 mg 2 to 4 times daily.

**Diabetes insipidus centralis**
Average dosage for adults: 200 mg 2 to 3 times daily.

**Special populations**
Tegretol should be prescribed only after a critical benefit-risk appraisal and under close monitoring in patients with a history of cardiac, hepatic, or renal damage, adverse haematological reactions to other drugs, or interrupted courses of therapy with Tegretol.

**Renal impairment/ Hepatic impairment**
No data are available on the pharmacokinetics of carbamazepine in patients with impaired hepatic or renal function.

**Pediatrics, children, and adolescents dosage**

**Epilepsy**

**Oral forms**
For children aged 4 years or less, a starting dose of 20 to 60 mg/day, increasing by 20 to 60 mg every second day, is recommended. For children over the age of 4 years, therapy may begin with 100 mg/day, increasing at weekly intervals by 100 mg.

Maintenance dosage: 10 to 20 mg/kg body weight daily in divided doses, e.g.
Up to 1 year of age: 100 to 200 mg daily (5 mL to 10 mL)
1 to 5 years of age: 200 to 400 mg daily (10 mL to 20 mL)
6 to 10 years of age: 400 to 600 mg daily (20 mL to 30 mL)
11 to 15 years of age: 600 to 1000 mg daily (30 mL to 50 mL)
>15 years of age: 800 to 1200 mg daily (same as adult dose)

*Note: one 5 mL measure of syrup is equivalent to 100 mg carbamazepine.*
Maximum recommended dose
Up to 6 years of age: 35 mg/kg/day
6-15 years of age: 1000 mg/day
>15 years of age: 1200 mg/day

**Diabetes insipidus centralis**
In children the dosage should be reduced proportionally to the child's age and body weight.

**Geriatric patients (65 years or above)**

**Trigeminal neuralgia**
Due to drug interactions and different antiepileptic drug pharmacokinetics, the dosage of Tegretol should be selected with caution in elderly patients.

In elderly patients, an initial dose of 100 mg twice daily is recommended. The initial dosage of 100 mg twice daily should be slowly raised daily until freedom from pain is achieved (normally at 200 mg 3 to 4 times daily). The dosage should then be gradually reduced to the lowest possible maintenance level. Maximum recommended dose is 1200 mg/day. When pain relief has been obtained, attempts should be made to gradually discontinue therapy, until another attack occurs.

**Method of Administration**
The tablets and the syrup (to be shaken before use) may be taken during, after, or between meals. Tablets should be taken with a little liquid.

The CR tablets (either whole or, if so prescribed, only half a tablet) should be swallowed unchewed with a little liquid. The syrup is particularly suitable for patients who have difficulty in swallowing tablets or need initial careful adjustment of the dosage.

As a result of slow, controlled release of the active substance from the CR tablets, these are designed to be taken in a twice-daily dosage regimen.

Since a given dose of Tegretol Syrup will produce higher peak levels than the same dose in tablet form, it is advisable to start with low doses and increase slowly so as to avoid adverse reactions.

**Switching patients from Tegretol tablets to syrup**
This should be done by giving the same number of mg per day in smaller, more frequent doses (e.g. Syrup three times a day (t.i.d.) instead of tablets twice a day (b.i.d)).

**Switching patients from conventional tablets to CR tablets**
Clinical experience shows that in some patients the dosage in the form of CR tablets may need to be increased.

4.3 **Contraindications**

- Known hypersensitivity to carbamazepine or structurally related drugs (e.g. tricyclic antidepressants) or any other component of the formulation
• Patients with atrioventricular block
• Patients with a history of bone-marrow depression
• Patients with a history of hepatic porphyrias (e.g. acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda)
• The use of Tegretol is contraindicated in combination with monoamine-oxidase inhibitors (MAOIs) (see Interactions).

4.4 Special warnings and precautions for use

Tegretol should be given only under medical supervision. Tegretol should be prescribed only after a critical benefit-risk appraisal and under close monitoring in patients with a history of cardiac, hepatic, or renal damage, adverse haematological reactions to other drugs, or interrupted courses of therapy with Tegretol.

Haematological effects
Agranulocytosis and aplastic anaemia have been associated with Tegretol; however, due to the very low incidence of these conditions, meaningful risk estimates for Tegretol are difficult to obtain. The overall risk in the general untreated population has been estimated at 4.7 persons per million per year for agranulocytosis and 2.0 persons per million per year for aplastic anaemia.

Transient or persistent decreased platelet or white blood cell counts occur occasionally to frequently in association with the use of Tegretol. However, in the majority of cases these effects prove transient and are unlikely to signal the onset of either aplastic anaemia or agranulocytosis. Nonetheless, complete pretreatment blood counts, including platelets (and possibly reticulocytes and serum iron), should be obtained at baseline, and periodically thereafter.

If the white blood cell or platelet count is definitely low or decreased during treatment, the patient and the complete blood count should be closely monitored. Tegretol should be discontinued if any evidence of significant bone-marrow depression appears.

Patients should be made aware of early toxic signs and symptoms of a potential haematological problem, as well as symptoms of dermatological or hepatic reactions. If reactions such as fever, sore throat, rash, ulcers in the mouth, easy bruising, petechial or purpuric haemorrhage appear, the patient should be advised to consult the physician immediately.

Serious dermatologic reactions
Serious dermatologic reactions, including toxic epidermal necrolysis (TEN; also known as Lyell’s syndrome) and Stevens-Johnson syndrome (SJS), have been reported very rarely with Tegretol. Patients with serious dermatological reactions may require hospitalization, as these conditions may be life-threatening and may be fatal. Most of the SJS/TEN cases appear in the first few months of treatment with Tegretol. These reactions are estimated to occur in 1 to 6 per 10,000 new users in countries with mainly Caucasian populations. If signs and symptoms suggestive of severe skin reactions (e.g. SJS, Lyell’s syndrome/TEN) appear, Tegretol should be withdrawn at once and alternative therapy should be considered.
Pharmacogenomics
There is growing evidence of the role of different HLA alleles in predisposing patients to immune-mediated adverse reactions.

Association with HLA-A*3101
Human Leukocyte Antigen (HLA)-A*3101 may be a risk factor for the development of hypersensitivity syndrome and cutaneous adverse drug reactions such as SJS, TEN, DRESS, AGEP and maculopapular rash (see Warnings and precautions: Hypersensitivity). Retrospective genome-wide studies in Japanese and Northern European populations reported association between severe skin reactions (SJS, TEN, DRESS, AGEP and maculopapular rash) associated with carbamazepine use and the presence of the HLA-A*3101 allele in these patients.

The frequency of the HLA-A*3101 allele varies widely between ethnic populations and its frequency is about 2 to 5% in European populations and about 10% in the Japanese population. The frequency of this allele is estimated to be less than 5% in the majority of Australian, Asian, African and North American populations, with some exceptions within 5-12%. Prevalence above 15% has been estimated in some ethnic groups in South America (Argentina and Brazil), North America (US Navajo and Sioux, and Mexico Sonora Seri) and Southern India (Tamil Nadu) and between 10%-15% in other native ethnicities in these same regions.

The allele frequencies listed here represent the percentage of chromosomes in the specified population that carry the allele of interest, meaning that the percentage of patients who carry a copy of the allele on at least one of their two chromosomes (i.e. the “carrier frequency”) is nearly twice as high as the allele frequency. Therefore, the percentage of patients who may be at risk is nearly twice the allele frequency.

Testing for the presence of HLA-A*3101 allele should be considered in patients with ancestry in genetically at-risk populations (for example, patients of the Japanese and Caucasian populations, patients who belong to the indigenous populations of the Americas, Hispanic populations, people of southern India, and people of Arabic descent), prior to initiating treatment with Tegretol (see Information for Healthcare professionals in this section). The use of Tegretol should be avoided in patients who are found to be positive for HLA-A*3101, unless the benefits clearly outweigh the risks. Screening is generally not recommended for any current Tegretol users, as the risk of SJS/TEN, AGEP, DRESS and maculopapular rash is largely confined to the first few months of therapy, regardless of HLA-A*3101 status.

Association with HLA-B*1502
Retrospective studies in patients of Han Chinese and Thai origin found a strong correlation between SJS/TEN skin reactions associated with carbamazepine and the presence in these patients of the Human Leukocyte Antigen (HLA)-B*1502 allele. The frequency of HLA-B*1502 allele ranges from 2 to 12% in Han Chinese populations and is about 8% in Thai populations. Higher reporting rates of SJS (rare rather than very rare) are reported in some countries in Asia (e.g. Taiwan, Malaysia and the Philippines) in which there is a higher frequency of the HLA-B*1502 allele in the population e.g. above 15% in the Philippines and some Malaysian populations. Allele frequencies up to about 2% and 6% have been reported in Korea and India, respectively. The frequency of the HLA-B*1502 allele is negligible in persons
of European descent, several African populations, indigenous peoples of the Americas, Hispanic populations sampled and in Japanese (<1%).

The allele frequencies listed here represent the percentage of chromosomes in the specified population that carry the allele of interest, meaning that the percentage of patients who carry a copy of the allele on at least one of their two chromosomes (i.e., the “carrier frequency”) is nearly twice as high as the allele frequency. Therefore, the percentage of patients who may be at risk is nearly twice the allele frequency.

Testing for the presence of HLA-B*1502 allele should be considered in patients with ancestry in genetically at-risk populations, prior to initiating treatment with Tegretol (see Information for Healthcare professionals in this section). The use of Tegretol should be avoided in tested patients who are found to be positive for HLA-B*1502 unless the benefits clearly outweigh the risks. HLA-B*1502 may be a risk factor for the development of SJS/TEN in Chinese patients taking other anti-epileptic drugs (AED) associated with SJS/TEN. Consideration should therefore be given to avoiding use of other drugs associated with SJS/TEN in HLA-B*1502 positive patients, when alternative therapies are otherwise equally acceptable. Screening is not generally recommended in patients from populations in which the prevalence of HLA-B*1502 is low. Screening is generally not recommended for any current Tegretol users, as the risk of SJS/TEN is largely confined to the first few months of therapy, regardless of HLA-B*1502 status.

The identification of subjects carrying the HLA-B*1502 allele and the avoidance of carbamazepine therapy in these subjects has been shown to decrease the incidence of carbamazepine-induced SJS/TEN.

**Limitation of genetic screening**

Genetic screening results must never substitute for appropriate clinical vigilance and patient management. Many Asian patients positive for HLA-B*1502 and treated with Tegretol will not develop SJS/TEN and patients negative for HLA-B*1502 of any ethnicity can still develop SJS/TEN. Similarly many patients positive for HLA-A*3101 and treated with Tegretol will not develop SJS, TEN, DRESS, AGEP or maculopapular rash and patients negative for HLA-A*3101 of any ethnicity can still develop these severe cutaneous adverse reactions. The role of other possible factors in the development of, and morbidity from these severe cutaneous adverse reactions, such as AED dose, compliance, concomitant medications, co-morbidities, and the level of dermatologic monitoring have not been studied.

**Information for Healthcare professionals**

If testing for the presence of the HLA-B*1502 allele is performed, high-resolution “HLA-B*1502 genotyping” is recommended. The test is positive if either one or two HLA-B*1502 alleles are detected and negative if no HLA-B*1502 alleles are detected. Similarly if testing for the presence of the HLA-A*3101 allele is performed, high-resolution “HLA-A*3101 genotyping” respectively is recommended. The test is positive if either one or two HLA-A*3101 alleles are detected and negative if no HLA- A*3101 alleles are detected.

**Other dermatologic reactions**

Mild skin reactions, e.g. isolated macular or maculopapular exanthema, can also occur and are mostly transient and not hazardous. They usually disappear within a few days or weeks, either
during the continued course of treatment or following a decrease in dosage. However, since it may be difficult to differentiate the early signs of more serious skin reactions from mild transient reactions, the patient should be kept under close surveillance with consideration given to immediately withdrawing the drug should the reaction worsen with continued use. The HLA-A*3101 allele has been found to be associated with less severe adverse cutaneous reactions from carbamazepine and may predict the risk of these reactions from carbamazepine, such as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption). However, The HLA-B*1502 allele has not been found to predict the risk of these aforementioned skin reactions.

**Hypersensitivity**

Class I (immediate) hypersensitivity reactions including rash, pruritus, urticaria, angioedema and reports of anaphylaxis have been reported with Tegretol. If a patient develops these reactions after treatment with Tegretol, the drug must be discontinued, and an alternative treatment started.

Tegretol may trigger hypersensitivity reactions, including Drug Rash with Eosinophilia and Systemic Symptoms (DRESS), a delayed multi-organ hypersensitivity disorder with fever, rash, vasculitis, lymphadenopathy, pseudolymphoma, arthralgia, leukopenia, eosinophilia, hepatosplenomegaly, abnormal liver function tests and vanishing bile duct syndrome (destruction and disappearance of the intrahepatic bile ducts), that may occur in various combinations. Other organs may also be affected (e.g. lungs, kidneys, pancreas, myocardium and colon). (See Adverse drug reactions section).

Patients who have exhibited hypersensitivity reactions to carbamazepine should be informed that approximately 25 to 30% of these patients may experience hypersensitivity reactions with oxcarbazepine (Trileptal®).

Cross-hypersensitivity can occur between carbamazepine and aromatic antiepileptic drugs (e.g. phenytoin, primidone and phenobarbital).

In general, if signs and symptoms suggestive of hypersensitivity reactions occur, Tegretol should be withdrawn immediately.

**Seizures**

Tegretol should be used with caution in patients with mixed seizures, which includes absences, either typical or atypical. In all these conditions, Tegretol may exacerbate seizures. In the event of exacerbation of seizures, Tegretol should be discontinued.

**Hepatic function**

Baseline and periodic evaluations of hepatic function must be performed during treatment with Tegretol, particularly in patients with a history of liver disease and in elderly patients. The drug should be withdrawn immediately in cases of aggravated liver dysfunction or active liver disease.

**Renal function**

Baseline and periodic complete urinalysis and BUN determinations are recommended.
Hyponatremia
Hyponatremia is known to occur with carbamazepine. In patients with pre-existing renal conditions associated with low sodium or in patients treated concomitantly with sodium-lowering medicinal products (e.g. diuretics, medicinal products associated with inappropriate ADH secretion), serum sodium levels should be measured prior to initiating carbamazepine therapy. Thereafter, serum sodium levels should be measured after approximately two weeks and then at monthly intervals for the first three months during therapy, or according to clinical need. These risk factors may apply especially to elderly patients. If hyponatraemia is observed, water restriction is an important counter-measurement if clinically indicated.

Hypothyroidism
Carbamazepine may reduce serum concentrations of thyroid hormones through enzyme induction requiring an increase in dose of thyroid replacement therapy in patients with hypothyroidism. Hence thyroid function monitoring is suggested to adjust the dosage of thyroid replacement therapy.

Anticholinergic effects
Tegretol has shown mild anticholinergic activity. Patients with increased intraocular pressure and urinary retention should therefore be closely observed during therapy (see Adverse drug reactions).

Psychiatric effects
The possibility of activation of a latent psychosis and, in elderly patients, of confusion or agitation should be borne in mind.

Suicidal ideation and behaviour
An analysis of reports of suicidality (suicidal behaviour or ideation) from placebo-controlled clinical studies of eleven medicines used to treat epilepsy as well as psychiatric disorders, and other conditions revealed that patients receiving anti-epileptic drugs had approximately twice the risk of suicidal behaviour or ideation (0.43%) compared to patients receiving placebo (0.22%). The increased risk of suicidal behaviour and suicidal ideation was observed as early as one week after starting the anti-epileptic medicine and continued through 24 weeks. The results were generally consistent among the eleven medicines. Patients who were treated for epilepsy, psychiatric disorders, and other conditions were all at increased risk for suicidality when compared to placebo, and there did not appear to be a specific demographic subgroup of patients to which the increased risk could be attributed. The relative risk for suicidality was higher in the patients with epilepsy compared to patients who were given one of the medicines in the class for psychiatric or other conditions.

All patients who are currently taking or starting on any anti-epileptic drug should be closely monitored for notable changes in behaviour that could indicate the emergence or worsening of suicidal thoughts or behaviour or depression.

Health Care Professionals should inform patients, their families, and caregivers of the potential for an increase in the risk of suicidality. Prescribers should advise patients to seek medical advice immediately if they develop any symptoms suggestive of suicidality.

Pregnancy and females of reproductive potential
Carbamazepine may be associated with fetal harm when administered to a pregnant woman (see section 4.6 Fertility, pregnancy and lactation). Tegretol should be used during pregnancy...
only if the potential benefit justifies the potential risks, following careful consideration of alternative suitable treatment options.

The woman should be fully informed of and understand the risk of potential harm to the foetus if carbamazepine is taken during pregnancy and therefore the importance of planning any pregnancy. Adequate counselling should be made available to all pregnant women and women of childbearing potential, regarding the risks associated with pregnancy due to potential teratogenic risk to the foetus (see section 4.6 Fertility, pregnancy and lactation).

Women of childbearing potential should use effective contraception during treatment with carbamazepine and for 2 weeks after the last dose (see below sub-section “Endocrinological effects” and section 4.5 Interaction with other medicinal products and other forms of interaction and section 4.6 Fertility, pregnancy and lactation). Before the initiation of treatment with carbamazepine in a woman of childbearing potential, pregnancy testing should be considered. If a woman is planning to become pregnant, all efforts should be made to switch to appropriate alternative treatment prior to conception and before contraception is discontinued. If a woman becomes pregnant while taking carbamazepine, she should be referred to a specialist to reassess carbamazepine treatment and consider alternative treatment options.

Endocrinological effects
Breakthrough bleeding has been reported in women taking Tegretol while using hormonal contraceptives. The reliability of hormonal contraceptives may be adversely affected by Tegretol and women of child-bearing potential should be advised to consider using alternative forms of birth control while taking Tegretol.

Monitoring of plasma levels
Although correlations between dosage and plasma levels of carbamazepine, and between plasma levels and clinical efficacy or tolerability are rather tenuous, monitoring of the plasma levels may be useful in the following situations: dramatic increase in seizure frequency/verification of patient compliance; during pregnancy; when treating children or adolescents; in suspected absorption disorders; in suspected toxicity when more than one drug is being used (see Interactions).

Dose reduction and withdrawal effects
Abrupt withdrawal of Tegretol may precipitate seizures, therefore carbamazepine should be withdrawn gradually over a 6-month period. If treatment with Tegretol has to be withdrawn abruptly in a patient with epilepsy, the switch to the new antiepileptic compound should be made under cover of a suitable drug.

Special ExcipientsTegretol Syrup contains parahydroxybenzoates which may cause allergic reactions (possibly delayed).

It also contains sorbitol and, therefore, should not be administered to patients with rare hereditary problems of fructose intolerance.

Falls
Tegretol treatment has been associated with ataxia, dizziness, somnolence, hypotension, confusional state, sedation (see section 7 Adverse drug reactions) which may lead to falls and, consequently fractures or other injuries. For patients with diseases, conditions, or medications
that could exacerbate these effects, complete risk assessment of fall should be considered recurrently for patients on long-term Tegretol treatment.

Non-clinical safety data
Non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity, genotoxicity and carcinogenic potential.

Genotoxicity
Carbamazepine was not found to be genotoxic in various standard bacterial and mammalian mutagenicity studies.

Carcinogenicity
In rats treated with carbamazepine for 2 years, the incidence of tumors of the liver was found to be increased. The significance of these findings relative to the use of carbamazepine in humans is unknown at present.

Excipients with known effect
Tegretol syrup contains the excipient propylene glycol (PG), which is generally considered safe. However, in the neonate, if high doses or prolonged administration are warranted, PG toxicity can occur. Effects such as lactic acidosis, central nervous system depression/toxicity, hyperosmolarity, haemolysis, cardiac arrhythmia and seizures have been observed.

4.5 Interaction with other medicinal products and other forms of interaction

Cytochrome P450 3A4 (CYP3A4) is the main enzyme catalyzing formation of the active metabolite carbamazepine-10,11-epoxide. Human microsomal epoxide hydrolase has been identified as the enzyme responsible for the formation of the 10,11-transdiol derivative from carbamazepine-10,11 epoxide. Co-administration of inhibitors of CYP3A4 or inhibitors of epoxide hydrolase with carbamazepine can which could induce adverse reactions (increase of carbamazepine or carbamazepine-10,11-epoxide plasma concentrations respectively). The dosage of Tegretol should be adjusted accordingly and/or the plasma levels monitored.

Co-administration of CYP3A4 inducers might increase the rate of carbamazepine metabolism, thus leading to potential decreases in the carbamazepine serum level and therapeutic effect. Similarly, discontinuation of a CYP3A4 inducer may decrease the rate of metabolism of carbamazepine, leading to an increase in carbamazepine plasma levels. The dose of Tegretol may have to be adjusted.

Carbamazepine is a potent inducer of CYP3A4 and other phase I and phase II enzyme systems in the liver, and may therefore reduce plasma concentrations of co-medications mainly metabolized by CYP3A4 by induction of their metabolism.

Female patients of childbearing potential should be warned that the concurrent use of Tegretol with hormonal contraceptives may render this type of contraceptive ineffective (see Endocrinological effects). Alternative non-hormonal forms of contraception are recommended when using Tegretol (see Women of child-bearing potential, pregnancy, breast-feeding and fertility).
Interactions resulting in a contraindication
The use of Tegretol is contraindicated in combination with monoamine-oxidase inhibitors (MAOIs); before administering Tegretol MAOIs should be discontinued for a minimum of 2 weeks, or longer if the clinical situation permits (see Effect of Tegretol on plasma levels of concomitant agents).

Agents that may raise carbamazepine plasma levels
Since raised plasma carbamazepine levels may result in adverse reactions (e.g. dizziness, drowsiness, ataxia, diplopia), the dosage of Tegretol should be adjusted accordingly and/or the plasma levels monitored when used concomitantly with the substances described below.

Analgesics, anti-inflammatory drugs:
dextropropoxyphene, ibuprofen

Androgens: danazol
Antibiotics: macrolide antibiotics (e.g. erythromycin, troleandomycin, josamycin, clarithromycin), ciprofloxacin
Antidepressants: possibly desipramine, fluoxetine, fluvoxamine, nefazodone, paroxetine, trazodone, viloxazine.
Antiepileptics: stiripentol, vigabatrin
Antifungals: azoles (e.g. itraconazole, ketoconazole, fluconazole, voriconazole). Alternative anticonvulsants may be recommended in patients treated with voriconazole or itraconazole
Antihistamines: terfenadine
Antipsychotics: olanzapine
Antituberculosis: isoniazid
Antivirals: protease inhibitors for HIV treatment (e.g. ritonavir)
Carbonic anhydrase inhibitors: acetazolamide
Cardiovascular drugs: diltiazem, verapamil
Gastrointestinal drugs: possibly cimetidine, omeprazole
Muscle relaxants: oxybutynin, dantrolene
Platelet aggregation inhibitors: ticlopidine
Other interactions: grapefruit juice, nicotinamide (only in high dosage)

Agents that may raise the active metabolite carbamazepine-10,11-epoxide plasma levels
Since raised plasma carbamazepine-10,11-epoxide levels may result in adverse reactions (e.g. dizziness, drowsiness, ataxia, diplopia), the dosage of Tegretol should be adjusted accordingly and/or the plasma levels monitored when used concomitantly with the substances described below:
Antipsychotics: Loxapine, quetiapine
Antiepileptics: Primidone, pregabide, valproic acid, valpromide, brivaracetam
Hypnotics and sedatives: valnoctamide
Agents that may decrease carbamazepine plasma levels

The dose of Tegretol may have to be adjusted when used concomitantly with the substances described below.

**Antiepileptics**
- felbamate, methsuximide, oxcarbazepine, phenobarbital, phenytoin (to avoid phenytoin intoxication and subtherapeutic concentrations of carbamazepine it is recommended to adjust the plasma concentration of phenytoin to 13 micrograms/mL before adding carbamazepine to the treatment) and fosphenytoin, primidone, and, although the data are partly contradictory, possibly also clonazepam.

**Antiepileptics**
- clobazam, clonazepam, ethosuximide, felbamate, lamotrigine, eslicarbazepine, oxcarbazepine, primidone, tiagabine, topiramate, valproic acid, zonisamide. To avoid phenytoin intoxication and subtherapeutic concentrations of carbamazepine it is recommended to adjust the plasma concentration of phenytoin to 13 micrograms/mL before adding carbamazepine to the treatment. There have been rare reports of an increase in plasma mephenytoin levels

**Antineoplastics**
- cisplatin or doxorubicin

**Antineoplastics**
- itraconazole, voriconazole. Alternative anti-convulsants may be recommended in patients treated with voriconazole or itraconazole

**Anticoagulants:**
- oral anticoagulants (e.g. warfarin, phenprocoumon, dicoumarol, acenocoumarol, rivaroxaban, dabigatran, apixaban, edoxaban)

**Antidepressants:**
- bupropion, citalopram, mianserin, nefazodone, sertraline, trazodone, tricyclic antidepressants (e.g. imipramine, amitriptyline, nortriptyline, clomipramine).

**Antiemetics:**
- Aprepitant

**Antiepileptics**
- clobazam, clonazepam, ethosuximide, felbamate, lamotrigine, eslicarbazepine, oxcarbazepine, primidone, tiagabine, topiramate, valproic acid, zonisamide. To avoid phenytoin intoxication and subtherapeutic concentrations of carbamazepine it is recommended to adjust the plasma concentration of phenytoin to 13 micrograms/mL before adding carbamazepine to the treatment. There have been rare reports of an increase in plasma mephenytoin levels

**Antifungals**
- itraconazole, voriconazole. Alternative anti-convulsants may be recommended in patients treated with voriconazole or itraconazole

**Antihelmintics**
- praziquantel, albendazole

**Antineoplastics**
- imatinib, cyclophosphamide, lapatinib, temsirolimus

**Antiplatelet**
- ticagrelor

**Antipsychotics**
- clozapine, haloperidol and bromperidol, olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, paliperidone

**Antineoplastics**
- cisplatin or doxorubicin

**Antituberculosis**
- rifampicin

**Bronchodilators or anti-asthma drugs**
- theophylline, aminophylline

**Dermatological drugs:**
- isotretinoin

**Other interactions**
- herbal preparations containing St John's wort (Hypericum perforatum).

**Effect of Tegretol on plasma levels of concomitant agents**

Carbamazepine may lower the plasma level, or diminish - or even abolish - the activity of certain drugs. Dose adjustments may be required for several medicines. Examples of such medicines are listed below. Note that the list does not include all affected medicines. For more information regarding how individual medicines are affected by induction, see also the product information of the co-administered medicine:

**Analgesics, anti-inflammatory agents**
- buprenorphine, methadone, paracetamol (long-term administration of carbamazepine and paracetamol may be associated with hepatotoxicity), phenazone (antipyrine), tramadol

**Antibiotics**
- doxycycline, rifabutin.

**Anticoagulants:**
- oral anticoagulants (e.g. warfarin, phenprocoumon, dicoumarol, acenocoumarol, rivaroxaban, dabigatran, apixaban, edoxaban)

**Antidepressants:**
- bupropion, citalopram, mianserin, nefazodone, sertraline, trazodone, tricyclic antidepressants (e.g. imipramine, amitriptyline, nortriptyline, clomipramine).

**Antiemetics:**
- Aprepitant

**Antiepileptics**
- clobazam, clonazepam, ethosuximide, felbamate, lamotrigine, eslicarbazepine, oxcarbazepine, primidone, tiagabine, topiramate, valproic acid, zonisamide. To avoid phenytoin intoxication and subtherapeutic concentrations of carbamazepine it is recommended to adjust the plasma concentration of phenytoin to 13 micrograms/mL before adding carbamazepine to the treatment. There have been rare reports of an increase in plasma mephenytoin levels

**Antifungals**
- itraconazole, voriconazole. Alternative anti-convulsants may be recommended in patients treated with voriconazole or itraconazole

**Antihelmintics**
- praziquantel, albendazole

**Antineoplastics**
- imatinib, cyclophosphamide, lapatinib, temsirolimus

**Antiplatelet**
- ticagrelor

**Antipsychotics**
- clozapine, haloperidol and bromperidol, olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, paliperidone

**Antineoplastics**
- cisplatin or doxorubicin

**Antituberculosis**
- rifampicin

**Bronchodilators or anti-asthma drugs**
- theophylline, aminophylline

**Dermatological drugs:**
- isotretinoin

**Other interactions**
- herbal preparations containing St John's wort (Hypericum perforatum).
<table>
<thead>
<tr>
<th>Category</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antivirals</td>
<td>protease inhibitors for HIV treatment (e.g. indinavir, ritonavir, saquinavir)</td>
</tr>
<tr>
<td>Anxiolytics</td>
<td>alprazolam, midazolam</td>
</tr>
<tr>
<td>Bronchodilators or anti-asthma drugs</td>
<td>theophylline</td>
</tr>
<tr>
<td>Contraceptives:</td>
<td>hormonal contraceptives (alternative contraceptive methods should be considered)</td>
</tr>
<tr>
<td>Cardiovascular drugs</td>
<td>calcium channel blockers (dihydropyridine group) e.g. felodipine, digoxin, simvastatin, atorvastatin, lovastatin, cerivastatin, ivabradine</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>tadalafil</td>
</tr>
<tr>
<td>Drugs used in erectile dysfunction</td>
<td>cyclosporin, everolimus, tacrolimus, sirolimus</td>
</tr>
<tr>
<td>Thyroid agents</td>
<td>levothyroxine</td>
</tr>
<tr>
<td>Other drug interactions</td>
<td>products containing oestrogens and/or progesterones</td>
</tr>
</tbody>
</table>

Combinations that require specific consideration

Concomitant use of carbamazepine and levetiracetam has been reported to increase carbamazepine-induced toxicity.

Concomitant use of carbamazepine and isoniazid has been reported to increase isoniazid-induced hepatotoxicity.

Combined use of carbamazepine and lithium or metoclopramide on the one hand, and carbamazepine and neuroleptics (haloperidol, thioridazine) on the other, may lead to increased neurological adverse reactions (with the latter combination even in the presence of ‘therapeutic plasma levels’).

Concomitant medication with Tegretol and some diuretics (hydrochlorothiazide, furosemide) may lead to symptomatic hyponatraemia.

Carbamazepine may antagonize the effects of non-depolarizing muscle relaxants (e.g. pancuronium). Their dosage may need to be raised, and patients should be monitored closely for more rapid recovery from neuromuscular blockade than expected.

Carbamazepine, like other psychoactive drugs, may reduce alcohol tolerance. It is therefore advisable for the patient to abstain from alcohol.

Concomitant use of carbamazepine with direct acting oral anti-coagulants (rivaroxaban, dabigatran, apixaban, and edoxaban) may lead to reduced plasma concentrations of direct acting oral anti-coagulants, which carries the risk of thrombosis. Therefore, if a concomitant use is necessary, close monitoring of signs and symptoms of thrombosis is recommended.

Interference with serological testing

Carbamazepine may result in false positive perphenazine concentrations in HPLC analysis due to interference.
Carbamazepine and the 10,11-epoxide metabolite may result in false positive tricyclic antidepressant concentration in fluorescence polarized immunoassay method.

4.6 Fertility, pregnancy and lactation

Pregnancy

In animals (mice, rats, rabbits) oral administration of carbamazepine during organogenesis led to increased embryonic mortality at daily doses which caused maternal toxicity (above 200 mg/kg body weight daily, i.e. 10 to 20 times the usual human dosage). In the rat there was also some evidence of abortion at 300 mg/kg body weight daily. Near-term rat foetuses showed growth retardation, again at maternally toxic doses. There was no evidence of teratogenic potential in the three animal species tested, but, in one study using mice, carbamazepine (40 to 240 mg/kg body weight daily, orally) caused defects (mainly dilatation of cerebral ventricles) in 4.7% of exposed foetuses as compared with 1.3% in controls.

Risk summary

Offspring of epileptic mothers are known to be more prone to developmental disorders, including malformations. Although conclusive evidence from controlled studies with carbamazepine monotherapy is lacking, developmental disorders and malformations, including spina bifida and also other congenital anomalies, e.g. craniofacial defects, cardiovascular malformations, hypospadias and anomalies involving various body systems, have been reported in association with the use of Tegretol.

Based on data in a North American pregnancy registry, the rate of major congenital malformations, defined as a structural abnormality with surgical, medical, or cosmetic importance, diagnosed within 12 weeks of birth following maternal exposure to carbamazepine monotherapy in the first trimester was 3.0% (95% CI 2.1-4.2%). As compared to pregnant women not taking any antiepileptic drug, the relative risk was 2.7 (95% CI 1.1-7.0). There is evidence to suggest that the risk of malformation with carbamazepine may be dose-dependent.

Neurodevelopmental disorders have been reported among children born to women with epilepsy treated with carbamazepine alone or in combination with other antiepileptic drugs during pregnancy. Studies related to the risk of neurodevelopmental disorders in children exposed to carbamazepine during pregnancy are contradictory and a risk cannot be excluded.

Specialist medical advice regarding the potential risks to a foetus caused by both seizures and antiepileptic treatment should be given to all women of childbearing potential taking antiepileptic treatment, and especially to women planning pregnancy and women who are pregnant.

Clinical considerations

Taking these data into consideration:

- Pregnant women with epilepsy should be treated with special care.

- If women receiving Tegretol become pregnant or plan to become pregnant, or if the need of initiating treatment with Tegretol arises during pregnancy, the drug's expected benefits
must be carefully weighed against its possible hazards, particularly in the first 3 months of pregnancy.

- In women of child-bearing potential Tegretol should, wherever possible, be prescribed as monotherapy, because the incidence of congenital abnormalities in the offspring of women treated with a combination of antiepileptic drugs is greater than in those of mothers receiving the individual drugs as monotherapy. The risk of malformations following exposure to carbamazepine as polytherapy may vary depending on the specific drugs used and may be higher in polytherapy combinations that include valproate.

- Minimum effective doses should be given and monitoring of plasma levels is recommended. The plasma concentration could be maintained in the lower side of the therapeutic range 4 to 12 micrograms/mL provided seizure control is maintained (See Dosage and administration: Epilepsy). There is evidence to suggest that the risk of malformation with carbamazepine may be dose-dependent, i.e. at a dose < 400 mg per day, the rates of malformation were lower than with higher doses of carbamazepine.

- Patients should be counseled regarding the possibility of an increased risk of malformations and given the opportunity of antenatal screening.

- During pregnancy, an effective antiepileptic treatment should not be interrupted, since the aggravation of the illness is detrimental to both the mother and the foetus.

**Monitoring and prevention**

Folic acid deficiency is known to occur in pregnancy. Antiepileptic drugs have been reported to aggravate folic acid deficiency. This deficiency may contribute to the increased incidence of birth defects in the offspring of treated epileptic women. Folic acid supplementation has therefore been recommended before and during pregnancy. Folic acid supplementation (5 mg) should be commenced four weeks prior to and continue for twelve weeks after conception.

**In the neonate**

In order to prevent bleeding disorders in the offspring, it has also been recommended that vitamin K1 be given to the mother during the last weeks of pregnancy as well as to the neonate.

There have been a few cases of neonatal seizures and/or respiratory depression associated with maternal Tegretol and other concomitant anticonvulsant drug use. A few cases of neonatal vomiting, diarrhoea and/or decreased feeding have also been reported in association with maternal Tegretol use. These reactions may represent a neonatal withdrawal syndrome.

**Lactation**

**Risk summary**

Carbamazepine passes into the breast milk (about 25 to 60% of plasma concentrations). The benefits of breast-feeding should be weighed against the remote possibility of adverse effects occurring in the infant. Mothers taking Tegretol may breast-feed their infants, provided the infant is observed for possible adverse reactions (e.g. excessive somnolence, allergic skin reaction). There have been some reports of cholestatic hepatitis in neonates exposed to carbamazepine during antenatal and or during breast feeding. Therefore breast-fed infants of
mothers treated with carbamazepine should be carefully observed for adverse hepatobiliary effects.

Females and males of reproductive potential

Contraception
Women of childbearing potential should use effective contraception during treatment with Tegretol and for 2 weeks after the last dose. Due to enzyme induction, Tegretol may result in a failure of the therapeutic effect of hormonal contraceptive drugs containing oestrogen and/or progesterone. Women of child-bearing potential should be advised to use alternative contraceptive methods while on treatment with Tegretol.

Fertility
There have been very rare reports of impaired male fertility and/or abnormal spermatogenesis.

4.7 Effects on ability to drive and use machines

The patient's ability to react may be impaired by the medical condition, resulting in seizures, and adverse reactions including dizziness, drowsiness, ataxia, diplopia, impaired accommodation and blurred vision have been reported with Tegretol, especially at the start of treatment or in connection with dose adjustments. Patients should therefore exercise due caution when driving a vehicle or operating machinery.

4.8 Undesirable effects

Summary of the safety profile
Particularly at the start of treatment with Tegretol, or if the initial dosage is too high, or when treating elderly patients, certain types of adverse reaction occur very commonly or commonly, e.g. CNS adverse reactions (dizziness, headache, ataxia, drowsiness, fatigue, diplopia), gastrointestinal disturbances (nausea, vomiting), and allergic skin reactions.

The dose-related adverse reactions usually abate within a few days, either spontaneously or after a transient dosage reduction. The occurrence of CNS adverse reactions may be a manifestation of relative overdosage or significant fluctuation in plasma levels. In such cases it is advisable to monitor plasma levels.

Tabulated summary of adverse drug reactions compiled from clinical trials and from spontaneous reports

Adverse drug reactions from clinical trials (Table 1) are listed by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse drug reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).

Table 1
**Blood and lymphatic system disorders**

<table>
<thead>
<tr>
<th>Type</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common</td>
<td>Leukopenia</td>
</tr>
<tr>
<td>Common</td>
<td>Thrombocytopenia, eosinophilia</td>
</tr>
<tr>
<td>Rare</td>
<td>Leukocytosis, lymphadenopathy</td>
</tr>
<tr>
<td>Very rare</td>
<td>Agranulocytosis, aplastic anaemia, pancytopenia, aplasia pure red cell, anaemia, anaemia megaloblastic, reticulocytosis, haemolytic anaemia</td>
</tr>
</tbody>
</table>

**Immune system disorders**

<table>
<thead>
<tr>
<th>Type</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare</td>
<td>A delayed multiorgan hypersensitivity disorder with fever, rashes, vasculitis, lymphadenopathy, pseudo lymphoma, arthralgia, leukopenia, eosinophilia, hepato-splenomegaly, abnormal liver function tests and vanishing bile duct syndrome (destruction and disappearance of the intrahepatic bile ducts), occurring in various combinations. Other organs may also be affected (e.g. lungs, kidneys, pancreas, myocardium, colon)</td>
</tr>
<tr>
<td>Very rare</td>
<td>Anaphylactic reaction, angioedema, hypogammaglobulinaemia</td>
</tr>
</tbody>
</table>

**Endocrine disorders**

<table>
<thead>
<tr>
<th>Type</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common</td>
<td>Oedema, fluid retention, weight increase, hyponatraemia and blood osmolarity decreased due to an antidiuretic hormone (ADH)-like effect leading in rare cases to water intoxication accompanied by lethargy, vomiting, headache, confusional state, neurological disorders</td>
</tr>
<tr>
<td>Very rare</td>
<td>Galactorrhoea, gynecomastia</td>
</tr>
</tbody>
</table>

**Metabolism and nutrition disorders**

<table>
<thead>
<tr>
<th>Type</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare</td>
<td>Folate deficiency, decreased appetite, anorexia</td>
</tr>
<tr>
<td>Very rare</td>
<td>Porphyria acute (acute intermittent porphyria and variegate porphyria), porphyria non-acute (porphyria cutanea tarda)</td>
</tr>
</tbody>
</table>

**Psychiatric disorders**

<table>
<thead>
<tr>
<th>Type</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare</td>
<td>Hallucinations (visual or auditory), depression, aggression, agitation, restlessness, aggression, agitation, confusional state</td>
</tr>
<tr>
<td>Very rare</td>
<td>Activation of psychosis</td>
</tr>
</tbody>
</table>

**Nervous system disorders**

<table>
<thead>
<tr>
<th>Type</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common</td>
<td>Ataxia, dizziness, somnolence,</td>
</tr>
<tr>
<td>Common</td>
<td>Diplopia, headache</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Abnormal involuntary movements (e.g. tremor, asterixis, dystonia, tics); nystagmus</td>
</tr>
<tr>
<td>Rare</td>
<td>Orofacial dyskinesia, eye movement disorder, speech disorders (e.g. dysarthria, slurred speech), choreoathetosis, neuropathy peripheral, paraesthesia, paresis</td>
</tr>
<tr>
<td>Very rare</td>
<td>Neuroleptic malignant syndrome, aseptic meningitis with myoclonus and peripheral eosinophilia, dysgeusia</td>
</tr>
</tbody>
</table>

**Eye disorders**

<table>
<thead>
<tr>
<th>Type</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common</td>
<td>Accommodation disorders (e.g. blurred vision)</td>
</tr>
<tr>
<td>Very rare</td>
<td>Lenticular opacities, conjunctivitis</td>
</tr>
</tbody>
</table>

**Ear and labyrinth disorders**

<table>
<thead>
<tr>
<th>Type</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very rare</td>
<td>Hearing disorders, e.g. tinnitus, hyperacusis, hypoacusis, change in pitch perception</td>
</tr>
</tbody>
</table>

**Cardiac disorders**

<table>
<thead>
<tr>
<th>Type</th>
<th>Conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rare</td>
<td>Cardiac conduction disorders</td>
</tr>
<tr>
<td><strong>Very rare:</strong></td>
<td>arrhythmia, atrioventricular block with syncope, bradycardia, circulatory collapse, cardiac failure congestive, coronary artery disease aggravated</td>
</tr>
<tr>
<td><strong>Vascular disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Rare:</strong></td>
<td>hypertension or hypotension</td>
</tr>
<tr>
<td><strong>Very rare:</strong></td>
<td>circulatory collapse, embolism (e.g. pulmonary embolism), thrombophlebitis</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Very rare:</strong></td>
<td>pulmonary hypertensitivity characterized e.g. by fever, dyspnoea, pneumonia</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Very common:</strong></td>
<td>vomiting, nausea</td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>dry mouth; with suppositories, rectal irritation may occur</td>
</tr>
<tr>
<td><strong>Uncommon:</strong></td>
<td>diarrhoea, constipation</td>
</tr>
<tr>
<td><strong>Rare:</strong></td>
<td>abdominal pain</td>
</tr>
<tr>
<td><strong>Very rare:</strong></td>
<td>pancreatitis, glossitis, stomatitis</td>
</tr>
<tr>
<td><strong>Hepatobiliary disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Rare:</strong></td>
<td>hepatitis of cholestatic, parenchymal (hepatocellular) or mixed type, vanishing bile duct syndrome, jaundice</td>
</tr>
<tr>
<td><strong>Very rare:</strong></td>
<td>hepatic failure, granulomatous liver disease</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Very common:</strong></td>
<td>urticaria which may be severe, dermatitis allergic</td>
</tr>
<tr>
<td><strong>Uncommon:</strong></td>
<td>dermatitis exfoliative and erythroderma</td>
</tr>
<tr>
<td><strong>Rare:</strong></td>
<td>systemic lupus erythematosus, pruritus</td>
</tr>
<tr>
<td><strong>Very rare:</strong></td>
<td>Stevens-Johnson syndrome*, toxic epidermal necrolysis, photosensitivity reaction, erythema multiforme, erythemanodosum, pigmentation disorder, purpura, acne, hyperhydrosis, alopecia, hirsutism</td>
</tr>
<tr>
<td><strong>Musculoskeletal, connective tissue and bone disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Rare</strong></td>
<td>muscular weakness</td>
</tr>
<tr>
<td><strong>Very rare:</strong></td>
<td>bone metabolism disorders (decrease in plasma calcium and blood 25-hydroxy-cholecalciferol) leading to osteomalacia/osteoporosis, arthralgia, myalgia, muscle spasms</td>
</tr>
<tr>
<td><strong>Renal and urinary disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Very rare:</strong></td>
<td>tubulointerstitial nephritis, renal failure, renal impairment (e.g. albuminuria, haematuria, oliguria, and blood urea increased/azotemia), urinary retention, urinary frequency</td>
</tr>
<tr>
<td><strong>Reproductive system</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Very rare:</strong></td>
<td>sexual dysfunction/erectile dysfunction, spermatogenesis abnormal (with decreased sperm count and/or motility)</td>
</tr>
<tr>
<td><strong>General disorders and administration site conditions</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Very common:</strong></td>
<td>fatigue</td>
</tr>
<tr>
<td><strong>Investigations</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Very common:</strong></td>
<td>gamma-glutamyltransferase increased (due to hepatic enzyme induction), usually not clinically relevant</td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>blood alkaline phosphatase increased</td>
</tr>
<tr>
<td><strong>Uncommon:</strong></td>
<td>transaminases increased</td>
</tr>
</tbody>
</table>
Very rare: intraocular pressure increased, blood cholesterol increased, high density lipoprotein increased, blood triglycerides increased. Thyroid function test abnormal: decreased L-Thyroxin (free thyroxine, thyroxine, tri-iodothyronine) and increased blood thyroid stimulating hormone, usually without clinical manifestations, blood prolactin increased.

*In some Asian countries also reported as rare. See also Warnings and precautions for use.

"Emergence or worsening of existing depression, suicidal behaviour and suicidal ideation has been reported in patients treated with antiepileptic agents in several indications. The frequency of these events is unknown."

Additional adverse drug reactions from spontaneous reports (frequency not known):
The following adverse drug reactions have been derived from post-marketing experience with Tegretol via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known. Adverse drug reactions are listed according to system organ classes in MedDRA. Within each system organ class, ADRs are presented in order of decreasing seriousness.

Table 2

| Infections and infestations: | Reactivation of Human herpesvirus 6 (HHV-6) infection |
| Blood and lymphatic system disorders: | Bone marrow failure |
| Injury, poisoning and procedural complications | Fall (associated with Tegretol treatment induced ataxia, dizziness, somnolence, hypotension, confusional state, sedation) (see section 4.4 Special warning and precautions for use). |
| Nervous system disorders: | Sedation, memory impairment |
| Gastrointestinal disorders: | Colitis |
| Immune system disorders: | Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) |
| Skin and subcutaneous tissue disorders: | Acute Generalized Exanthematous Pustulosis (AGEP) lichenoid keratosis, onychomadesis |
| Musculoskeletal and connective tissue disorders: | Fracture |
| Investigations: | Bone density decreased |

4.9 Overdose

Signs and symptoms
The presenting signs and symptoms of overdosage usually involve the central nervous, cardiovascular, respiratory systems and reactions mentioned under Adverse drug reactions.

Central nervous system: CNS depression; disorientation, depressed level of consciousness, somnolence, agitation, hallucination, coma; blurred vision, slurred speech, dysarthria, nystagmus, ataxia, dyskinesia, initially hyper-reflexia, later hyporeflexia;
convulsions, psychomotor disturbances, myoclonus, hypothermia, mydriasis.

**Respiratory system**
Respiratory depression, pulmonary oedema.

**Cardiovascular system**
Tachycardia, hypotension, at times hypertension, conduction disturbance with widening of QRS complex; syncope in association with cardiac arrest.

**Gastrointestinal system**
Vomiting, delayed gastric emptying, reduced bowel motility.

**Musculoskeletal system**
There have been some cases which reported rhabdomyolysis in association with carbamazepine toxicity.

**Renal function**
Retention of urine, oliguria or anuria; fluid retention, water intoxication due to an ADH-like effect of carbamazepine.

**Laboratory findings**
Hyponatraemia, possibly metabolic acidosis, possibly hyperglycaemia, increased muscle creatine phosphokinasae.

**Management**
There is no specific antidote.

**For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).**

Management should initially be guided by the patient's clinical condition; admission to hospital. Measurement of the plasma level to confirm carbamazepine poisoning and to ascertain the size of the overdose.

Evacuation of the stomach and administration of activated charcoal. Delay in evacuating the stomach may result in delayed absorption, leading to relapse during recovery from intoxication. Supportive medical care in an intensive care unit with cardiac monitoring and careful correction of electrolyte imbalance.

**Special recommendations**
Charcoal hemoperfusion has been recommended. Hemodialysis is the effective treatment modality in the management of the carbamazepine overdose. Relapse and aggravation of symptomatology on the 2\textsuperscript{nd} and 3\textsuperscript{rd} day after overdose, due to delayed absorption, should be anticipated.
5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

**Mechanism of action (MOA)**

The mechanism of action of carbamazepine, the active substance of Tegretol, has only been partially elucidated. Carbamazepine stabilizes hyperexcited nerve membranes, inhibits repetitive neuronal discharges, and reduces synaptic propagation of excitatory impulses. It is conceivable that prevention of repetitive firing of sodium-dependent action potentials in depolarized neurons via use- and voltage-dependent blockade of sodium channels may be its main mechanism of action.

Whereas reduction of glutamate release and stabilization of neuronal membranes may account mainly for the antiepileptic effects, the depressant effect on dopamine and noradrenaline turnover could be responsible for the antimanic properties of carbamazepine.

**Pharmacotherapeutic group, ATC**

Therapeutic class: antiepileptic, neurotropic, and psychotropic agent; (ATC Code: N03 AF01).

Dibenzazepine derivative.

Pharmacodynamics (PD) As an antiepileptic agent its spectrum of activity embraces: partial seizures (simple and complex) with and without secondary generalization; generalized tonic-clonic seizures, as well as combinations of these types of seizures.

In clinical studies Tegretol given as monotherapy to patients with epilepsy - in particular children and adolescents - has been reported to exert a psychotropic action, including a positive effect on symptoms of anxiety and depression as well as a decrease in irritability and aggressiveness. As regards cognitive and psychomotor performance, in some studies equivocal or negative effects, depending also upon dosages administered, were reported. In other studies, a beneficial effect on attentiveness, cognitive performance/memory was observed.

As a neurotropic agent Tegretol is clinically effective in a number of neurological disorders, e.g. it prevents paroxysmal attacks of pain in idiopathic and secondary trigeminal neuralgia; in addition, it is used for the relief of neurogenic pain in a variety of conditions, including tabes dorsalis, post-traumatic paresthesia, and post-herpetic neuralgia; in alcohol-withdrawal syndrome it raises the lowered convulsion threshold and improves withdrawal symptoms (e.g. hyperexcitability, tremor, impaired gait); in diabetes insipidus centralis, Tegretol reduces the urinary volume and relieves the feeling of thirst.

As a psychotropic agent Tegretol proved to have clinical efficacy in affective disorders, i.e. as treatment for acute mania as well as for maintenance treatment of (manic-depressive) bipolar affective disorders, when given either as monotherapy or in combination with neuroleptics, antidepressants, or lithium, in excited schizo-affective disorder and excited mania in combination with other neuroleptics, and in rapid cycling episodes.

**Clinical efficacy and safety**

No recent clinical trials have been conducted with Tegretol.
5.2 Pharmacokinetic properties

Absorption
Carbamazepine is absorbed almost completely but relatively slowly from the tablets. The conventional tablets and the chewable tablets yield mean peak plasma concentrations of the unchanged substance within 12 and 6 hours, respectively, following single oral doses. With the Syrup, mean peak plasma concentrations are attained within 2 hours, and with the suppositories within a mean of 12 hours. With respect to the amount of active substance absorbed, there is no clinically relevant difference between the oral dosage forms. After a single oral dose of 400 mg carbamazepine (tablets) the mean peak concentration of unchanged carbamazepine in the plasma is approx. 4.5 micrograms/mL.

When CR tablets are administered singly and repeatedly, they yield about 25% lower peak concentrations of active substance in plasma than the conventional tablets; the peaks are attained within 24 hours. The CR tablets provide a statistically significant decreased fluctuation index, but not a significant decreased Cmin at steady state. The fluctuation of the plasma concentrations with a twice-daily dosage regimen is low. The bioavailability of Tegretol CR tablets is about 15% lower than that of the other oral dosage forms.

Steady-state plasma concentrations of carbamazepine are attained within about 1 to 2 weeks, depending individually upon auto-induction by carbamazepine and hetero-induction by other enzyme-inducing drugs, as well as on pretreatment status, dosage, and duration of treatment. The steady-state plasma concentrations of carbamazepine considered as ‘therapeutic range’ vary considerably interindividually: for the majority of patients a range between 4 to 12 micrograms/mL corresponding to 17 to 50 micromol/L has been reported. Concentrations of carbamazepine-10,11-epoxide (pharmacologically active metabolite): about 30% of carbamazepine levels.

Ingestion of food has no significant influence on the rate and extent of absorption, regardless of the dosage form of Tegretol.

Distribution
Assuming complete absorption of carbamazepine, the apparent volume of distribution ranges from 0.8 to 1.9 L/kg.

Carbamazepine crosses the placental barrier.

Carbamazepine is bound to serum proteins to the extent of 70 to 80%. The concentration of unchanged substance in cerebrospinal fluid and saliva reflects the non-protein bound portion in the plasma (20 to 30%). Concentrations in breast milk were found to be equivalent to 25 to 60% of the corresponding plasma levels.

Biotransformation/ metabolism
Carbamazepine is metabolized in the liver, where the epoxide pathway of biotransformation is the most important one, yielding the 10,11-transdiol derivative and its glucuronide as the main metabolites. Cytochrome P450 3A4 has been identified as the major isoform responsible for the formation of the pharmacologically active carbamazepine-10,11 epoxide from carbamazepine. Human microsomal epoxide hydrolase has been identified as the enzyme responsible for the formation of the 10,11-transdiol derivative from carbamazepine-10,11
epoxide. 9-Hydroxy-methyl-10-carbamoyl acridan is a minor metabolite related to this pathway. After a single oral dose of carbamazepine about 30% appears in the urine as end-products of the epoxide pathway. Other important biotransformation pathways for carbamazepine lead to various monohydroxylated compounds, as well as to the N-glucuronide of carbamazepine produced by UGT2B7.

**Elimination**

The elimination half-life of unchanged carbamazepine averages approx. 36 hours following a single oral dose, whereas after repeated administration it averages only 16 to 24 hours (auto-induction of the hepatic mono-oxygenase system), depending on the duration of the medication. In patients receiving concomitant treatment with other liver-enzyme inducing drugs (e.g. phenytoin, phenobarbitone), half-life values averaging 9 to 10 hours have been found.

The mean elimination half-life of the 10,11-epoxide metabolite in the plasma is about 6 hours following single oral doses of the epoxide itself. After administration of a single oral dose of 400 mg carbamazepine, 72% is excreted in the urine and 28% in the faeces. In the urine, about 2% of the dose is recovered as unchanged drug and about 1% as the pharmacologically active 10,11-epoxide metabolite.

**Characteristics in patients**

**Special populations**

**Paediatric patients**

Owing to enhanced carbamazepine elimination, children may require higher doses of carbamazepine (in mg/kg) than adults.

**Elderly**

There is no indication of altered pharmacokinetics of carbamazepine in elderly patients as compared with young adults.

**Patients with hepatic or renal impairment**

No data are available on the pharmacokinetics of carbamazepine in patients with impaired hepatic or renal function.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

**Tablets:** colloidal silicon dioxide, microcrystalline cellulose, magnesium stearate, carmelllose sodium

**CR tablets:** colloidal silicon dioxide, ethylcellulose aqueous dispersion, microcrystalline cellulose), methacrylic acid copolymer, magnesium stearate, sodium carboxymethylcellulose, purified talc. **Coating:** hydroxypropyl methylcellulose, glyceryl polyoxyethylene glycol stearate, iron oxide red, iron oxide yellow, purified talc, titanium dioxide.

**Syrup:** powdered cellulose, sodium carboxymethylcellulose, caramel, methyl hydroxybenzoate, hydroxyethyl cellulose, propylene glycol, polyethylene glycol 400 stearate, propyl hydroxybenzoate, saccharin sodium, sorbic acid, sorbitol solution, purified water.
6.2 Incompatibilities

None known.

6.3 Shelf life

Tablets: 24 months  
CR tablets: 24 months  
Syrup: 36 months (or 60 months for AU formulation)

6.4 Special precautions for storage

Tablets: do not store above 25°C and protect from moisture.  
CR tablets: do not store above 25°C and protect from moisture.  
Syrup: do not store above 30°C and protect from light.

Tegretol must be kept out of the reach and sight of children.

6.5 Nature and contents of container

Tegretol 200 mg tablets: blisters containing 100 and 200 tablets  
Tegretol 400 mg tablets: blisters containing 100 tablets  
Tegretol CR 200 mg and 400 mg tablets: blisters containing 100 modified release tablets  
Tegretol syrup 5 mg/100 mL: glass bottle  
Pack sizes: Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

There are no specific instructions for use/handling.

7. MEDICINE SCHEDULE

Prescription medicine

8. SPONSOR

Novartis New Zealand Limited  
PO Box 99102  
Newmarket  
Auckland 1149

Telephone: 0800 354 335

9. DATE OF FIRST APPROVAL

Tegretol 200 mg and 400 mg tablet2: 31 December 1969  
Tegretol 100 mg/5 mL syrup: 28 January 1976  
Tegretol CR 200 mg and 400 mg modified release tablets: 28 October 1988
Tegretol 100 mg/5 mL syrup (Australian formula): 25 February 1999

10. DATE OF REVISION OF THE TEXT

8 May 2023

SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section 2</td>
<td>Addition of PG</td>
</tr>
<tr>
<td>Section 3</td>
<td>Addition of “The tablet can be divided into equal doses.”</td>
</tr>
<tr>
<td>Section 4.1</td>
<td>Addition of “Tegretol should not be used for status epilepticus.”</td>
</tr>
<tr>
<td>Section 4.2</td>
<td>Heading updates and special population information.</td>
</tr>
<tr>
<td>Section 4.4</td>
<td>Addition of excipients of known effect</td>
</tr>
<tr>
<td></td>
<td>Addition of information on hypersensitivity</td>
</tr>
<tr>
<td>Section 4.5</td>
<td>Addition of brivaracetam; removal of loratadine</td>
</tr>
<tr>
<td>Section 4.6</td>
<td>Addition of information on neurodevelopmental disorders, folic acid</td>
</tr>
<tr>
<td>Section 4.9</td>
<td>Removal of gastric lavage</td>
</tr>
</tbody>
</table>

Internal Document Code
tgr160523iNZ based on Novartis CDS dated 9 January 2023